Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7.
Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection. These DAAs, boceprevir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN and RBV. The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients. In this review, we present an overview of pharmacology, efficacy, adverse events, and emergence of resistance-associated variants with the use of these agents. As with all drugs, especially newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.
最近，直接作用抗病毒药物（DAAs）在丙型肝炎病毒（HCV）的治疗方面取得了重大进展。与聚乙二醇干扰素α（Peg-IFN）和利巴韦林（RBV）联合使用时，博赛泼维（boceprevir）和特拉泼维（telaprevir）这两种 DAAs 可显著提高持续病毒学应答率，适用于初治和经治的 HCV 基因型 1 感染患者。本文就这两种药物的药理学、疗效、不良反应和耐药相关变异的出现进行综述。与所有药物一样，尤其是新批准的药物，临床医生必须查阅药品说明书以获取详细的用药信息、所有报告的不良反应、禁忌证和药物相互作用。
